Is this biotech stock a no-brainer buy now after its huge FDA approval? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now.

DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...

Metsera is a clinical-stage biotechnology company developing injectable and oral treatments for obesity and related conditions, the filing shows. The company’s investors include affiliates of ...

The future of the Bay Area biotech firm Allakos was riding on one clinical trial, for a drug designed to treat the skin condition known as chronic spontaneous urticaria, or chronic hives.

DES MOINES, Iowa – A final report has been filed on the disposal of the 1.3 million chickens abandoned in the wake of a financial crisis at Pure Prairie Poultry. On October 2, 2024, the Iowa ...

Sam Altman, pictured at President Donald Trump's inauguration, is contributing to another round of funding for Retro Biosciences. © 2025 Fortune Media IP Limited ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...

Canada has long punched above its weight in life sciences and biotechnology, with many of the fundamental discoveries that underpin today’s important blockbuster drugs and therapeutic approaches ...

Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could ...

How will the Trump administration approach healthcare regulation? Will generalist investors remain wary of biotech? Can the industry’s expensive pivot into immunology and obesity deliver drugs ...

Ascentage sold 7,325,000 American Depositary shares at $17.25 each. Credit: Andrey Zhuravlev via Getty Images. China-based biotech Ascentage Pharma has raised $126m in a US initial public offering ...

Ab&B will go up against other local manufacturers if it launches the rabies vaccine in China but the rest of its pipeline could pit it against big Western drugmakers. The biotech has allocated ...